Herriot Tabuteau Sells 15,254 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CEO Herriot Tabuteau sold 15,254 shares of the firm’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $117.37, for a total value of $1,790,361.98. Following the sale, the chief executive officer owned 7,229 shares in the company, valued at $848,467.73. The trade was a 67.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Herriot Tabuteau also recently made the following trade(s):

• On Tuesday, September 16th, Herriot Tabuteau sold 19,719 shares of Axsome Therapeutics stock. The shares were sold at an average price of $114.19, for a total value of $2,251,712.61.
• On Friday, September 12th, Herriot Tabuteau sold 27,907 shares of Axsome Therapeutics stock. The stock was sold at an average price of $118.96, for a total value of $3,319,816.72.

Axsome Therapeutics Stock Up 1.7%

AXSM opened at $118.63 on Friday. The company has a market cap of $5.92 billion, a P/E ratio of -23.40 and a beta of 0.54. The business’s 50-day moving average price is $112.74 and its 200-day moving average price is $110.51. The company has a current ratio of 1.57, a quick ratio of 1.51 and a debt-to-equity ratio of 1.66. Axsome Therapeutics, Inc. has a 12 month low of $75.56 and a 12 month high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.08. The firm had revenue of $150.04 million for the quarter, compared to the consensus estimate of $140.02 million. Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%. On average, equities analysts expect that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Wells Fargo & Company upgraded Axsome Therapeutics to a “strong-buy” rating in a report on Wednesday, September 3rd. Royal Bank Of Canada lifted their price objective on Axsome Therapeutics from $184.00 to $189.00 and gave the stock an “outperform” rating in a report on Tuesday, August 5th. Bank of America lifted their price objective on Axsome Therapeutics from $173.00 to $176.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. HC Wainwright reiterated a “buy” rating and issued a $180.00 price objective on shares of Axsome Therapeutics in a report on Tuesday, June 10th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $150.00 target price on shares of Axsome Therapeutics in a research note on Monday, August 4th. Two analysts have rated the stock with a Strong Buy rating and thirteen have assigned a Buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $177.86.

Institutional Trading of Axsome Therapeutics

Large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd bought a new stake in shares of Axsome Therapeutics in the first quarter worth about $25,000. NBC Securities Inc. bought a new stake in Axsome Therapeutics during the 1st quarter valued at approximately $31,000. Quantbot Technologies LP bought a new stake in Axsome Therapeutics during the 1st quarter valued at approximately $31,000. AlphaQuest LLC bought a new stake in Axsome Therapeutics during the 1st quarter valued at approximately $38,000. Finally, Neo Ivy Capital Management bought a new stake in Axsome Therapeutics during the 1st quarter valued at approximately $41,000. 81.49% of the stock is owned by institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.